Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector
Sort by: Date|Relevance

This Unique App “Matches the Perfect Customer to the Ideal Vehicle”

Negotiating a new vehicle purchase is often an exercise in futility and sometimes ends in frustration. Now, there’s a Canadian company that’s offering a unique new app that makes the entire purchase and financing easy. How? By bringing the ve...
Dave Jackson | May 2, 2022 |

Leap Therapeutics Lunges Forward on $132M Licensing Deal and $27M Equity Raise

Shares of Leap Therapeutics jumped 60% after the company reported that it signed an exclusive option and license agreement for its immuno-oncology drug DKN-01 with BeiGene in the Asia Pacific region excluding Japan. The firm also secured an additional $27 million in equity fin...
Streetwise Reports | January 6, 2020 |

Biotech Announces Deal with Bayer on Non-Hormonal Contraception

Details of the arrangement and an update on the company's pipeline are provided in a Dawson James report. In a Jan. 13 research note, Dawson James Securities analyst Jason Kolbert reported that Daré Bioscience Inc. (DARE:NASDAQ) partnered with Bayer, the company beh...
Streetwise Reports | January 16, 2020 |

Apple's (NASDAQ: AAPL) bet on Liquidmetal about to pay off?

Apple Inc. ( NASDAQ: AAPL , Stock Forum ) loves to think of lucrative new uses for other people's bright ideas. For instance, the original iPod wouldn't have been possible without Toshiba's innovative 1.8-inch hard drive. And when Steve Jobs learned about Gorilla Glass...
David Zeiler | October 28, 2012 |

Why XOM is close to an ideal option trading candidate

XOM has a hugely active options series, trades in both monthly and weekly expiration series and has bid / ask spreads that are just a few pennies wide. One of the most interesting aspects of options is the myriad opportunities presented for high probability trades for thos...
J.W. Jones | February 6, 2013 |

Fineqia: Building the digital asset ecosystem

Fineqia International is a Vancouver-based asset manager with a strategic focus on the decentralized and WEB 3.0 economy. Joining us here at the Top Line today is CEO Bundeep Rangar, thanks for joining us today. TMH: To start off with, give our viewers an overvie...
Sabrina Cuthbert | February 1, 2023 |

Avedro Shares Looking Up 35% with Glaukos Merger

Avedro Inc. and Glaukos Corp. announced that the firms' boards of directors have executed a definitive merger agreement. The all-stock deal is expected to close in Q4/19. After the markets closed yesterday afternoon, corneal modeling platform firm Avedro Inc...
Streetwise Reports | August 13, 2019 |

Ra Pharmaceuticals Shares Up 100% Following $2.1 Billion Takeover Bid

Shares of Ra Pharmaceuticals doubled today after the firm announced that it will be acquired by Belgian firm UCB for $48 per share in an all cash deal. Prior to the market open this morning Ra Pharmaceuticals Inc. (RARX:NASDAQ) and Brussels-based UCB (UCB:Euronext)...
Streetwise Reports | October 11, 2019 |

XPhyto: Why Rapid PCR Testing is Here to Stay

Regular coronavirus testing is destined to become the norm for many years to come, regardless of how many people get vaccinated against COVID-19. So says Hugh Rogers, the CEO of XPhyto Therapeutics Corp. ( CSE: XPHY ) (FSE: 4XT) ( OTC: XPHYF ) , a Canadian life scie...
Marc Davis | April 22, 2021 |

Can NervGen keep a lid on explosive news?

Speculation of early “evidence” of successful proof-of-concept human trials sparks stock rallies Trial volunteers taking a placebo are offered the real deal in a follow-up trial as a “reward” The company&Clo...
Knox Henderson | March 20, 2024 |
1 2 3 4 5 6 7 8 9 10 ...